Navigation Links
SomaGenics' sshRNA Technology Demonstrates Efficacy of RNAi Against Hepatitis C Virus
Date:9/20/2011

SANTA CRUZ, Calif., Sept. 20, 2011 /PRNewswire/ -- SomaGenics, Inc., a biotechnology company specializing in RNA-based technologies, presented exciting data on the efficacy of RNA interference (RNAi) therapeutics against Hepatitis C virus (HCV) based on the company's sshRNA platform.

SomaGenics, along with its collaborators at Tekmira Pharmaceuticals and Roche, presented the results in a poster entitled "Synthetic Short shRNAs are Potent Inhibitors of Hepatitis C Virus in HCV-Infected Chimeric Mice" at the 7th Annual Meeting of the Oligonucleotide Therapeutics Society held September 8-10, 2011 in Copenhagen, Denmark.

"The demonstration of a strong antiviral effect in the chimeric human liver mouse model further reinforces our confidence in the therapeutic potential of our sshRNA platform. We are quite excited about the performance of SomaGenics' synthetic sshRNAs formulated with Tekmira's lipid nanoparticles (LNPs), which demonstrated reduction of circulating HCV load by more than two orders of magnitude. The results presented affirm the advantages of our approach to combine multiple sshRNA targeting otherwise 'undruggable' viral targets," said Dr. Brian Johnston, Chief Executive of SomaGenics.

Some conclusions of the scientific presentation:

  • This represents the first demonstration of in vivo efficacy of RNAi against HCV infection;
  • LNP-formulated sshRNAs were efficiently taken up by human liver cells in a chimeric mouse model;
  • Significant HCV reduction (2.0 log10 viral load reduction) was achieved with a single i.v. dose;
  • Viral load was still depressed by 1.0 log10 three weeks after dosing;
  • Maximal anti-viral effect was observed with two doses of a cocktail of two sshRNAs targeting separate sites on the HCV genome, where a total viral load reduction of 2.5 log10 was achieved.
  • The LNP-formulated sshRNAs were well tolerated with no evidence of liver toxicity; and
  • The therapeutic effect was convincingly demonstrated to act through an RNAi mechanism.

About Hepatitis C Virus

HCV is a leading cause of cirrhosis, liver cancer, and liver failure requiring liver transplant. An estimated 170 million people are infected with HCV globally, with 3-4 million new infections each year. No vaccine for HCV is currently available.

About RNAi and SomaGenics' sshRNA Technology

The Nobel-prize-winning discovery of RNA interference (RNAi), a process by which double-stranded RNA molecules can inhibit the function of virtually any gene, has spurred interest in the development of short interfering RNAs as drugs. SomaGenics has pioneered the discovery and development of a unique class of short interfering RNAs called sshRNAs. Structurally distinct from the more commonly used siRNAs and expressed shRNAs, sshRNAs are short, chemically modified RNA sequences that are chemically synthesized as single strands. They have outstanding potency and possess attractive pharmacokinetic properties without undesirable immune stimulation.  

About SomaGenics

SomaGenics is a privately held company that develops innovative RNA technologies for therapeutic and diagnostic uses. SomaGenics' lead therapeutic program, against hepatitis C virus, has successfully completed efficacy evaluations in preclinical animal models and is ready for clinical development.

Contact:

Dr. Sumedha Jayasena
VP, Therapeutic Development
2161 Delaware Avenue
Santa Cruz, CA 95060
sjayasena@somagenics.com
805-341-5163
http://www.somagenics.com

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>
SOURCE SomaGenics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. U of T-led research improves performance of next-generation solar cell technology
2. Eppendorf Licenses Technology for Thermal Cyclers to Bulldog Bio
3. TWi Biotechnology Successfully Completes Patient Recruitment for Phase IIb Trial of AC-201 for the Treatment of Type II Diabetes
4. AIT unveils portfolio of 16 nanotechnology products
5. Industrial Biotechnology China News 1108
6. New Videos Spotlight Science/Technology Careers and Educational Path To Secure Jobs in Them
7. Unexpected adhesion properties of graphene may lead to new nanotechnology devices
8. NeoStem Announces the Receipt of Over $1,700,000 in DOD Funding for its VSEL™ Technology Being Developed to Treat Osteoporosis
9. Better desalination technology key to solving worlds water shortage
10. Amarantus BioSciences and Generex Biotechnology Collaborate on Cell Therapy for Late Stage Diabetes
11. HumanTouch 21st on Washington Technologys "Fast 50" list
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... 23, 2016 On Wednesday, June 22, ... down 0.22%; the Dow Jones Industrial Average edged 0.27% lower ... 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the following ... Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... a new line of intelligent tools designed, tuned and optimized exclusively for Okuma ... 12–17 in Chicago. The result of a collaboration among several companies with expertise ...
(Date:6/22/2016)... DIEGO , June 22, 2016 ... that will allow them to produce up to ... from one lot within one week. These high-quality, ... time laboriously preparing cells and spend more time ... possible through a proprietary, high-volume manufacturing process that ...
Breaking Biology Technology:
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
(Date:4/14/2016)... Israel , April 14, 2016 ... Authentication and Malware Detection, today announced the appointment of ... assumed the new role. Goldwerger,s leadership appointment ... on the heels of the deployment of its platform ... BioCatch,s behavioral biometric technology, which discerns unique cognitive and ...
Breaking Biology News(10 mins):